Trials / Approved For Marketing
Approved For MarketingNCT05722912
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Ruxolitinib Cream |
Timeline
- First posted
- 2023-02-10
- Last updated
- 2023-02-10
Source: ClinicalTrials.gov record NCT05722912. Inclusion in this directory is not an endorsement.